neuroClues announced a €10 million Series A funding round to accelerate the rollout of its AI-powered neurological biomarker platform across Europe, bringing its total capital raised to €25 million, including additional non-dilutive funding. The round was led by Teampact Ventures, White Fund, and the European Innovation Council Fund, with participation from existing investors including InvestBW, Leansquare, and Wallonie Entreprendre.
The company is addressing a longstanding gap in neurology, where clinical assessments have changed little in decades and often rely on subjective observation. Neurodegenerative diseases remain difficult to diagnose early, with misdiagnosis rates still significant and detection often occurring only after irreversible damage has occurred.
NeuroClues has developed a portable, CE-marked Class IIa medical device that captures high-speed infrared eye movement data and applies proprietary AI algorithms to generate objective neurological biomarkers within minutes. The system replaces traditional observational methods with quantified, reproducible data that can be integrated directly into clinical workflows.
Following CE certification in early 2025, the company has rapidly expanded its commercial footprint, deploying more than 30 devices across seven European countries, including France, Belgium, Italy, Germany, Switzerland, the Netherlands, and the United Kingdom. The platform is being used in hospitals, private neurology practices, and research centers, with growing demand driven by clinical adoption and peer recognition.
NeuroClues is also building clinical partnerships to expand its dataset and applications, including integration into cohorts at the Paris Brain Institute and participation in a large-scale study involving 25,000 participants to develop a normative database of oculomotor biomarkers. The company aims to use this data to enable earlier and more precise identification of neurological conditions such as Parkinson’s disease, Alzheimer’s disease, and concussion-related impairments.
To support commercialization, NeuroClues has appointed Bart Stulens, former VP Neuromodulation EMEA at Medtronic, as Chief Commercial Officer and is expanding its commercial team across Europe.
The company is also opening a limited €1.5 million tranche of the round to individual investors through LITA, allowing broader participation alongside institutional backers.
KEY QUOTES:
“Early detection will reshape neurology, and with it, entire health systems. neuroClues is one of the rare companies that has turned decades of academic research into a device that actually works in a doctor’s office, today. That combination of scientific depth and commercial readiness is why we led this round.”
Romain Vidal
“This Series A validates our technology and our ability to execute. CE certification in five months. First commercial deployments within weeks. A normative database project with 25,000 participants. Today, we give clinicians an objective way to assess neurological anomalies. As our dataset grows, our solution will help them identify specific pathologies earlier and more precisely than ever before. That is where we are headed.”
Antoine Pouppez
“The speed of clinical adoption since CE certification speaks for itself. neuroClues is solving a problem that every neurologist recognizes, and the market is responding.”
Olivier Legrain
“Objective eye movement evaluation can be considered as an early biomarker for Parkisnon’s disease before some clinical symptoms appear as for example gait and balance disorders or mild cognitive dysfunction. These are invaluable for understanding and monitoring neurological diseases. NeuroClues enables their use in everyday clinical settings, bridging research and real-world care.”
Marie Vidailhet
